Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Leukemia, Myeloid, Acute 17Myelodysplastic Syndromes 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Hematologic Neoplasms 9Myeloproliferative Disorders 8Multiple Myeloma 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Leukemia, Lymphocytic, Chronic, B-Cell 8Hodgkin Disease 7Lymphoma, Non-Hodgkin 6Graft vs Host Disease 6Waldenstrom Macroglobulinemia 5Lymphoma 5Burkitt Lymphoma 5Recurrence 4Primary Myelofibrosis 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Lymphoma, Mantle-Cell 4Leukemia, Prolymphocytic 4Leukemia, Myelomonocytic, Chronic 4Skin Neoplasms 3Sarcoma 3Rhabdomyosarcoma 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Biphenotypic, Acute 3Leukemia 3Bronchiolitis Obliterans Syndrome 3

Interventions

Sirolimus 2temsirolimus 1carbon-11 acetate 1Valproic Acid 1Respiratory Function Tests 1Phlebotomy 1Immunoglobulin G 1Imatinib Mesylate 1Genetic Testing 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphangioleiomyomatosis × Sirolimus × 1 year × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT03304678 2026-02-18

Discovery of Sirolimus Sensitive Biomarkers in Blood

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
33 enrolled 6 charts

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡